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A B S T R A C T
Background: One of the late complications associated with radiation therapy (RT) is a possible increased risk of
second cancer. In this systematic review, we analysed the incidence of rectal cancer following primary pelvic
cancer irradiation.
Methods: A literature search was conducted using the PubMed and EMBASE libraries. Original articles that
reported on secondary rectal cancer after previous RT for a primary pelvic cancer were included. Sensitivity
analyses were performed by correcting for low number of events, high risk of bias, and outlying results.
Results: A total of 5171 citations were identiﬁed during the literature search, 23 studies were included in the
meta-analyses after screening. A pooled analysis, irrespective of primary tumour location, showed an increased
risk for rectal cancer following RT (N=403.243) compared with non-irradiated patients (N=615.530) with a
relative risk (RR) of 1.43 (95% conﬁdence interval [CI] 1.18–1.72). Organ speciﬁc meta-analysis showed an
increased risk for rectal cancer after RT for prostate (RR 1.36, 95%CI 1.10–1.67) and cervical cancer (RR 1.61,
95% CI 1.10–2.35). No relation was seen in ovarian cancer patients. The modality of RT did not inﬂuence the
incidence of rectal cancer.
Conclusions: This review demonstrates an increased risk for second primary rectal cancer in patients who re-
ceived RT to the pelvic region. This increased risk was modest and could not be conﬁrmed for all primary pelvic
cancer sites. The present study does not provide data to change guidelines for surveillance for rectal cancer in
previously irradiated patients.
Introduction
Approximately 50% of all cancer patients undergo radiation therapy
(RT) as part of their primary treatment regimen [1]. During RT, high
dosages of ionizing radiation are delivered which generate oxygen-de-
rived free radicals. These radicals induce DNA damage and eventually
cause apoptosis [2,3]. The addition of RT to a treatment regimen is
generally associated with a reduction in recurrences and improvement
of prognosis in many types of cancer [4–8]. However, RT is also known
to cause acute and late toxicity. One form of late toxicity is a potentially
increased risk of secondary tumours in the irradiated ﬁeld.
During RT for cancer of one of the pelvic organs, the rectum is
usually within the ﬁeld of irradiation, and secondary rectal cancer has
been reported. Studies show conﬂicting data with respect to increased
risk on rectal cancer following pelvic radiation [9–14]. Lack of power
and variations in study design might explain these conﬂicts partially.
Moreover, all patients with a history of cancer, including those who did
not undergo RT, are at increased risk for the development of second
primary cancer [15]. Although secondary cancer development is a
multifactorial process, the exact role of RT in this remains unclear.
One of the challenges in the interpretation of studies on second
cancer incidence is that diﬀerent latency period thresholds are being
used. Latency periods represent the time from radiation exposure until
diagnosis of a subsequent cancer and latency period thresholds have
been introduced to second cancer analyses to reduce possible bias from
synchronous tumours. Between studies, latency period thresholds vary
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from 1month up to 10 years [16,17].
This systematic review generates insight into the incidence and la-
tency period of subsequent rectal cancer following primary pelvic
cancer irradiation through an overview of the literature and a meta-
analysis.
Methods
Literature search and selection criteria
A systematic search of all peer-reviewed literature was conducted
using the PubMed and EMBASE libraries on April 14th 2017. Reference
lists of selected studies were checked for relevant articles. The Boolean
search strategy is provided in Supplementary File 1 and included the
following terms and their synonyms: [“second primary neoplasm” OR
“radiation-induced neoplasm”] AND [“rectal neoplasm”] AND [(“ur-
eteral” OR “urinary bladder” OR “genital” OR “gynaecological” OR
“ovarian” OR “uterine” OR “endometrial” OR “cervical” OR “vaginal”
OR “vulvar” OR “prostate” OR “testicular”) AND “neoplasm”]. All
studies were reviewed for inclusion by two independent reviewers (AR
and JvB or NH). A title and abstract screening was performed followed
by full-text review. Any discrepancies were resolved through a con-
sensus discussion. Only original articles in the English language that
reported on second rectal cancer after previous RT for a primary pelvic
cancer were included. Studies were excluded if ‘colorectal cancer’ was
not subdivided into colon and/or rectal cancer. In case of considerable
overlap in data/subjects between studies, the study with the largest
population was included in the meta-analysis.
Data extraction
The goal was to compare patients who received RT for their primary
cancer with patients who did not receive RT for the primary cancer.
Therefore, we calculated the number of patients in each group and the
corresponding number of second rectal cancers. Data was extracted for
male and female patients separately. Some studies applied a threshold
Fig. 1. Flowchart of the search strategy for systematic review. *In case of considerable overlap in data/subjects between studies, the study with the largest population
was included in the meta-analysis. A reference list of studies that were excluded due to overlap in data is provided in Supplementary File 3.
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for the latency period to reduce bias from synchronous tumours when
multiple incidences were given for diﬀerent threshold latency periods,
all were extracted. In addition, data on RT regimen, follow-up, age, and
standardized incidence risk (SIR) were extracted when available.
Quality assessment
Risk of bias was assessed by the ‘Newcastle-Ottawa Scale (NOS)
[18], a tool designed for quality assessment of non-randomised studies
for meta-analysis (Table 3). Studies are rated on a 0–9 scale on items
regarding selection, comparability of subjects and exposure. The quality
of most reviewed studies was high (NOS score 7–9), only one study had
a high risk of bias (NOS score 5). Publication bias was analysed by
testing for funnel plot symmetry (Supplementary Fig. 1).
Statistical analysis
Patients who received RT were compared with patients who did not
receive RT. Studies in which a non-irradiated control group was lacking
and studies with zero events were excluded from meta-analysis and are
summarized in supplementary Table 1. Heterogeneity was tested by
Chi-square analysis and was deﬁned as present in case of a p-value <
0.10. To assess the impact of heterogeneity on the meta-analysis, I2 (the
percentage of variability in eﬀect estimates that is due to heterogeneity
rather than chance) was calculated. Furthermore, a random-eﬀects
model with inverse variance weighting of studies was used for meta-
analysis. This model incorporates heterogeneity by giving a weight to
each study equal to the inverse of the variance of the eﬀect estimate.
Results are depicted as risk ratios (RR) alongside a 95% conﬁdence
interval (CI). Sensitivity analyses were performed to assess the robust-
ness of the results by correcting for low number of events (≤5 events
per group), high risk of bias (total score < 6), and outlying results.
Subgroup analysis was performed to compare the diﬀerent primary
cancer sites and diﬀerent RT modalities (external beam radiation
therapy versus brachytherapy), and to analyse the inﬂuence of used
ﬁxed latency periods. Review Manager version 5.3 was used for the
meta-analysis (Copenhagen, the Nordic Cochrane Centre) [19].
Registration
The study design was registered and published at the PROSPERO
International prospective register of systematic reviews [20]. Regis-
tration number: CRD42017046045.
Results
Search results
A total of 5171 citations were identiﬁed during the literature search
(Fig. 1). After screening titles and abstracts, 128 studies were selected,
and 64 studies were selected on the basis of their full text. Studies with
overlapping data were excluded (n= 22). Studies without a non-irra-
diated control group (n= 15) and studies with zero events (n= 4) are
summarized in supplementary Table 1.
Subgroup analyses were performed for the diﬀerent primary cancer
sites. In male patients, the literature search revealed 16 studies that
reported on the risk of rectal cancer after RT for prostate cancer, and 10
studies after RT for testicular cancer. Nine and two studies were eligible
for meta-analysis, respectively. In female patients, nine studies were
identiﬁed after primary cervical cancer, of which six studies were eli-
gible for meta-analysis. Three studies were identiﬁed after primary
endometrial cancer, and all three were eligible for meta-analysis. The
literature search revealed four studies that investigated the risk of rectal
cancer after RT for ovarian cancer, of which three were included in the
meta-analysis. No studies were identiﬁed investigating the risk for
second primary rectal cancer following treatment for bladder or vaginalTa
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cancer. Data on studies that were included in the meta-analysis
(n= 18) are summarized in Table 1 for male patients and in Table 2 for
female patients. Data from studies reporting on testicular and en-
dometrial primary cancers are provided in the supplementary ﬁles only
(Supplementary ﬁle 2).
All primary cancer sites
A pooled analysis for all studies suitable for meta-analysis, irre-
spective of primary cancer location, showed an increased risk for rectal
cancer as a second primary in previously irradiated patients
(N= 403.243), compared with patients who did not undergo RT
(N=615.530; RR 1.43, 95% CI 1.18–1.72; Fig. 2a). Heterogeneity was
substantial (I2= 59%). Sensitivity analysis, excluding studies with≤ 5
events per group [17,21–25], high risk of bias [26], or outlying results
[27] did not change the results nor the level of heterogeneity (RR 1.44,
95%CI 1.21–1.72; I2= 59%). Subgroup analyses were performed for
the diﬀerent primary cancer sites.
Male patients
Prostate cancer
RT is used as deﬁnitive treatment for prostate cancer in approxi-
mately 25% of localized prostate cancer patients [28]. Dosages up to
80 Gy are delivered to the prostate, and as a result, the rectum, is ex-
posed to signiﬁcant dosages of radiation as well [29]. Patients who
underwent RT for prostate cancer (N=232,120) were at increased risk
for rectal cancer compared with patients who did not undergo RT as
part of their initial treatment (N= 487,703). The incidence of second
rectal cancer was 0.48% (N=1104) in irradiated patients and 0.41%
(N=1983) in non-irradiated patients (RR 1.36, 95% CI 1.10–1.67;
Fig. 2b). However, considerable heterogeneity was observed between
studies (I2= 44%). Sensitivity analyses, the exclusion of studies
with≤ 5 events per group [30], high risk of bias [31], or outlying result
[14], did not alter the outcomes.
Some studies reported an increased risk for rectal cancer after
prostate irradiation [27,31–34], whereas others found no association
[14,17,30,35]. Possible reasons for this discrepancy are a limited
sample size or short follow-up, diﬀerences in lag time periods and
Table 3
Assessment of methodological quality of included studies for meta-analysis based on the Newcastle-Ottawa Scale for cohort studies.
Location primary tumour Study (year) Selection Comparability Outcome/exposure Total (max 9)
Prostate Boorjian et al. [17] ★★★★ ★★ ★★ 8
Rapiti et al. [30] ★★★★ ★★ ★★ 8
Huo et al. [27] ★★★★ ★★ ★★★ 9
Bhojani et al. [32] ★★★★ ★★ ★★ 8
Hinnen et al. [14] ★★★ ★★ ★★ 7
Margel et al. [33] ★★★★ ★ ★★ 7
Hamilton et al. [35] ★★★★ ★★ ★★ 8
Joung et al. [31] ★★★★ ★★ 6
Hegemann et al. [65] ★★★★ ★ ★★ 7
Cervix Clarke et al. [22] ★★★★ ★★ 6
Boice et al. [41] ★★★ ★★★ 6
Hiyama et al. [23] ★★★★ ★★★ 7
Storm et al. [66] ★★★★ ★ ★★ 7
Arai et al. [21] ★★★★ ★★ 6
Kleinerman et al. [11] ★★★★ ★★ 6
Ovaries Reimer et al. [25] ★★★★ ★★★ 7
Prior et al. [24] ★★★★ ★★★ 7
Freedman et al. [26] ★★★★ ★ 5
Fig. 2a. Assessment of risk ratio of second primary rectal cancer following irradiation for a pelvic tumour, all primary cancer sites. RT, radiation therapy.
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variation in statistical methods. The latter is illustrated by the fact that
Baxter et al. reported an 1.7-fold increased risk of rectal cancer for
prostate cancer patients treated with RT compared to those treated
surgically [9], while Kendal et al. did not ﬁnd an increased risk using
the same SEER data [36]. Huo et al. expanded the SEER data until 2005
and demonstrated that there was indeed an increased risk for rectal
cancer, but only after > 10 years of follow-up [27]. In addition,
prostate cancer usually aﬀects men at older age (median 67–71 years in
the reviewed studies) which resulted in a limited follow-up time in
some of the studies.
Female patients
Cervical cancer
Approximately half of cervical cancer patients receive RT as part of
their treatment regimen [37]. A case-control study estimated that the
rectum receives 30–60 Gy of irradiation during RT for cervical cancer
[38]. Overall 5-year survival is up to 85% for early stage cervical
cancer, depending on the stage of disease [39]. Meta-analyses showed
an increased incidence of rectal cancer in patients treated with RT
(N=134,725) compared with non-irradiated patients (N=38,688).
The incidence of second rectal cancer was 0.28% (N=371) in irra-
diated patients and 0.18% (N=69) in non-irradiated patients (RR 1.61,
95% CI 1.10–2.35; Fig. 2c). Heterogeneity was moderate (I2= 37%).
Excluding studies with≤ 5 events per group [21–23] during sensitivity
analysis lowered heterogeneity to 20% and results were no longer
statistically signiﬁcant but showed a trend towards an increase of rectal
cancer after previous RT (RR 1.35, 95% CI 0.99–1.83). Studies that
could not be included into the meta-analysis also found an
increased incidence of rectal cancer in patients that received RT for a
primary cervical cancer, compared with the general population
[11,16,21,23,40,41].
Ovarian cancer
Less than 10% of primary ovarian cancer patients are treated with
RT as a component of the primary treatment [42]. Ovarian cancer is
relatively rare and the related mortality is high. Most patients present
with a late stage of disease and the 5-year survival rate is only 45–50%
[43,44].
The literature search revealed four studies that investigated the risk
of rectal cancer after RT for ovarian cancer, of which three were in-
cluded in the meta-analysis. The meta-analysis showed no statistically
signiﬁcant diﬀerence in the incidence of rectal cancer between irra-
diated (N=11,088) and non-irradiated patients (N=45,969). Second
rectal cancer occurred in 0.10% (N=11) of irradiated patients and in
0.16% (N=75) of non-irradiated patients (RR 0.38; 95%CI 0.05–3.11;
Fig. 2d). It should be taken into account that heterogeneity was high
between the studies (I2= 83%). Excluding studies with≤ 5 events per
group for sensitivity analysis would only leave one study for meta-
analysis and this study [26] had a relatively high risk of bias. In the
study that was excluded from the meta-analysis, the number of patients
included in the study (n=93) was too small to draw any conclusions
[45].
Type of radiation
The technique that is used to administer RT might inﬂuence the
probability of developing a second rectal cancer. This was suggested in
several studies [46–48] and might be related to diﬀerences in radiation
doses to which the rectum is exposed. Lönn et al. studied organ-speciﬁc
dose distributions of RT for endometrial cancer and estimated that the
average dose received by the rectum was 50 Gy for external beam RT
and 35 Gy for brachytherapy [49].
To further investigate this hypothesis, a subgroup analysis was
performed, including the studies in which information regarding the
type of radiation was given (Supplementary Fig. 2). External beam RT
(N=196,329) was compared with the application of brachytherapy
Fig. 2b. Assessment of risk ratio of second primary rectal cancer following irradiation for prostate cancer. RT, radiation therapy.
Fig. 2c. Assessment of risk ratio of second primary rectal cancer following irradiation for cervical cancer. RT, radiation therapy.
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(N= 188,828). A relation between the type of RT and the incidence of
rectal cancer could not be conﬁrmed. The RR for developing rectal
cancer was 1.36 (95% CI 1.19–1.56) in the external beam RT group and
0.98 (95%CI 0.43–2.21) in the brachytherapy group (P= 0.43). Het-
erogeneity was high (I2= 90%) due to inconsistent ﬁndings in the
brachytherapy group. Results did not change during sensitivity ana-
lysis. Unfortunately, information on RT doses was not provided in the
majority of the studies and this could therefore not be analysed.
Latency period
Several studies suggested that the incidence of rectal cancer might
increase with time [11,21,27,40,50]. A subgroup analysis was per-
formed according to the threshold of follow-up that was used, excluding
all rectal cancer events prior to the following time points: 0–2months
(N= 868.907), and 5 (N=9918), 10 (N=98,877), or 20 years
(N= 28,926; Supplementary Fig. 3). Some studies reported on multiple
ﬁxed latency periods and could therefore be entered into the meta-
analysis repetitively. There was a signiﬁcant increase of rectal cancers
in time since primary treatment with calculated RRs for developing
rectal cancer of 1.31 (95% CI 1.104–1.66), 1.51 (95% CI 0.97–2.33),
1.95 (95% CI 01.51–2.53), and 2.49 (95% CI 1.48–4.19), for 0–2 moths,
up to 5 years, up to 10 years and up to 20 years respectively
(P= 0.0006). The test for subgroup diﬀerences showed a heterogeneity
level (I2) of 61.8%. By performing sensitivity analysis, studies with≤ 5
events per group were excluded [22,25,30,51], as well as one study
with high risk of bias [26]. This did not change the results.
Discussion
Pelvic RT has been associated with a potentially increased risk for
secondary tumours. Especially the rectum, which is in close anatomical
relation to several pelvic target organs, is likely to be within the ﬁeld of
irradiation and can consequently receive relatively high doses of ra-
diation. The aim of this systematic review and meta-analysis was to
study the incidence of a second primary rectal cancer after previous RT
for a primary pelvic cancer. A pooled analysis, irrespective of primary
cancer location, showed an increased risk for rectal cancer following RT
(N=403.243) compared with non-irradiated patients (N= 615.530)
with a RR of 1.43 (95% CI 1.18–1.72). Organ speciﬁc meta-analysis
showed a statistically signiﬁcant increased risk for rectal cancer after
RT for prostate and cervical cancer. No relation was seen in ovarian
cancer patients. A possible explanation for this is that studies on the
incidence of rectal cancer following RT for ovarian cancer were scarce
due to a low incidence rate of the primary cancer itself, and the low
number of patients receiving RT. Also, the irradiation ﬁeld in ovarian
cancer is probably less likely to include the rectum. Finally, only few
studies have studied rectal cancer as a second primary tumour speci-
ﬁcally; a number of studies had to be excluded since data on second
colorectal cancers were not further subdivided into rectal cancer cases.
However, in the majority of these studies, colorectal cancer risk fol-
lowing RT was not increased [52–56]. There were no studies that in-
vestigated the risk for second primary rectal cancer following treatment
for bladder or vaginal cancer.
The results show that the incidence of rectal cancers after pelvic
radiation increases with time. The majority of tumours developed after
the regular follow-up period. However, given the relatively small in-
crease of rectal cancers due to RT, it does not seem beneﬁcial to in-
troduce a surveillance program for irradiated patients. Although the
risk for second rectal cancer is relatively small, it is important for
physicians and patients to be aware of this late complication of RT,
especially given the fact that it may alter treatment of rectal cancer due
to limitations in the possibility of additional use of RT [57,58].
In a previous nationwide study, with a median age of 66 and a
median follow-up of 8.1 years (range 0–27) in the irradiated group, we
showed that the incidence of second primary pelvic cancers was not
increased following RT for a primary rectal cancer [15]. Instead, a
protective eﬀect was seen for some of the cancer sites, predominantly
for the development of second primary prostate cancer. This has also
been observed by other study groups [13,59–61] and contrasts with the
current ﬁndings in which RT for a primary pelvic cancer results in an
increased risk for a second primary rectal cancer. In other words, pelvic
radiation seems to result in an increased risk for rectal cancer, but not
for other pelvic cancers. There is no clear explanation for this. The
bowel is prone to radiation toxicity with late/chronic proctitis occur-
ring in 5–20% of patients [62]. This condition might create a pre-
cancerous microenvironment, similar to chronic inﬂammatory bowel
diseases [63] such as Crohn’s or ulcerative colitis. Induction of chronic
inﬂammation by RT is less common in other organs. Hypothetically,
diﬀerences in RT ﬁelds or in doses of delivered scatter radiation might
also play a role, however, insuﬃcient data are available. Finally, dif-
ferences in age at onset of the primary cancer might play a role. One
could postulate that older patients have less chance to develop second
cancers due to a limited life expectancy. Although age was often not
subdivided for irradiated and non-irradiated patients in the included
studies, the mean age of patients did not seem to diﬀer greatly from the
previous nationwide study (Tables 1 and 2).
The quality of the reviewed studies was high, with low risks of bias.
This is probably related to the fact that most studies included data from
well-known population-based cancer registries, among which were
diﬀerent SEER registries and the Dutch, Danish and Israeli nationwide
cancer registries. The current study was limited by the absence of
uniformity in deﬁned latency periods (between radiation exposure and
diagnosis of rectal cancer) that were used in the reviewed studies.
Second malignancies diagnosed within a short time period after diag-
nosis of the initial cancer are often regarded as independent events
(synchronous tumours), also resulting from intensiﬁed medical sur-
veillance [33]. Therefore, a ﬁxed latency period is often introduced to
reduce the chances of such bias. The latency periods in the reviewed
studies varied between 1month up to 10 years, often without evidence
supporting the time thresholds. This may have led to heterogeneity in
the results.
Another possible bias arises from the uncertainty whether non-ir-
radiated patients received any kind of pelvic radiation after treatment
for the primary cancer. For example, in the study of Curtis et al., 70% of
patients had advanced endometrial cancer and some of these patients
might have received RT in any subsequent courses of treatment [12].
Mettlin et al. previously studied the completeness of cancer registries
Fig. 2d. Assessment of risk ratio of second primary rectal cancer following irradiation for ovarian cancer. RT, radiation therapy.
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and found that in 6% of prostate cancer patients, subsequent RT was
given after the primary treatment, but was not registered [64]. This
could have led to an underestimation of the inﬂuence of RT in the
development of second rectal cancer. In addition, information on other
possible predisposing factors, such as lifestyle factors or genetic sus-
ceptibility was not available in the reviewed studies. However, this
possible bias is expected to aﬀect both groups equally.
Conclusions
This systematic review and meta-analysis demonstrates an increased
risk for second primary rectal cancer in patients who received irradia-
tion to the pelvic region. This increased risk was modest and could not
be conﬁrmed for all diﬀerent types of primary pelvic cancer. Further
research, using large nationwide cohorts with more detailed informa-
tion should be performed to speciﬁcally study the incidence of rectal
cancer after treatment for other primary pelvic cancers. The present
study does not provide data to change guidelines for surveillance for
rectal cancer in previously irradiated patients.
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